Publications by authors named "Marie-Elodie Spaety"
Article Synopsis
- Platinum-based drugs are standard treatments for gastric cancer, but resistance due to genetic mutations and metabolic changes limits their effectiveness.
- The study presents RDC11, a new cycloruthenated compound that shows greater cytotoxicity and better tumor growth reduction compared to oxaliplatin.
- RDC11 works by targeting glutathione metabolism, lowering cellular GSH levels, increasing reactive oxygen species, and triggering apoptosis, making it a promising alternative to combat resistance to current treatments.
Gastric cancer (GC) remains a health issue due to the low efficiency of therapies, such as cisplatin. This unsatisfactory situation highlights the necessity of finding factors impacting GC sensibility to therapies. We analyzed the cisplatin pangenomic response in cancer cells and found HDAC4 as a major epigenetic regulator being inhibited.
View Article and Find Full Text PDFRuthenium complexes are considered as potential replacements for platinum compounds in oncotherapy. Their clinical development is handicapped by a lack of consensus on their mode of action. In this study, we identify three histones (H3.
View Article and Find Full Text PDF